FDA advisory panel unanimously recommends Moderna's mRNA flu vaccine, first of its kind

Newsmax—A key Food and Drug Administration advisory committee voted unanimously to recommend approval of Moderna's influenza vaccine — the first flu shot to use mRNA technology and the panel's first vaccine recommendation since 2023. The panel found the benefits outweighed the risks, particularly for older adults. The recommendation does not guarantee FDA approval, but the agency typically follows its advisers' guidance.

• Newsmax — FDA Panel Backs Flu Vaccine Using MRNA Technology - Newsmax
• NZ Herald — Technology news - NZ Herald
• PBS NewsHour — FDA panel backs first-of-its-kind flu vaccine using mRNA technology - PBS
• ScienceAlert — New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel
• The Hill — Advisory panel specifically recommended the mRNA flu shot for older adults
• Wall Street Journal — Panel voted to affirm the benefit-risk profile of Moderna's mRNA flu vaccine
• NPR — Panel's unanimous vote is the FDA committee's first vaccine recommendation since 2023
• Associated Press — FDA advisory panel unanimously backed the first mRNA-based flu vaccine